Literature DB >> 1331610

Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II.

H Sonobe1, Y Manabe, M Furihata, J Iwata, T Oka, Y Ohtsuki, H Mizobuchi, H Yamamoto, O Kumano, S Abe.   

Abstract

BACKGROUND: The line of differentiation in synovial sarcoma still remains controversial. Thus far, only a few human synovial sarcoma cell lines have been described. However, their morphologic characteristics have not been fully established. EXPERIMENTAL
DESIGN: We established a new synovial sarcoma cell line (HS-SY-II) from pleural effusion with lung metastasis in a typical example of the monophasic spindle cell type. The HS-SY-II cells, in vitro and in vivo, were examined by light microscopy, immunohistochemistry, electron microscopy, and cytogenetics.
RESULTS: The HS-SY-II cells showed a hypertriploid karyotype with complex chromosome abnormalities including pathognomonic t(X;18)(p11;q11), and have been stably maintained for more than 40 months in vitro, showing rather small spindle or polygonal shape without conspicuous pleomorphism. Histologic features of initially and serially transplanted tumors in nude mice were essentially the same as those of the original sarcoma, corresponding to the monophasic spindle cell variant with a prominent palisading pattern and calcified foci in parts. The HS-SY-II cells in vitro and in vivo similarly expressed vimentin and cytokeratin by immunohistochemistry, and also exhibit the same ultrastructural features such as irregularly shaped nuclei with prominent nucleoli, many paranuclearly running intermediate filaments, and filopodia-like processes.
CONCLUSIONS: This HS-SY-II cell line retaining the distinct morphological characteristics as the monophasic spindle cell type of synovial sarcoma therefore will be extremely useful for various pathomorphologic investigations on synovial sarcoma.

Entities:  

Mesh:

Year:  1992        PMID: 1331610

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha.

Authors:  M Nagai; S Tanaka; M Tsuda; S Endo; H Kato; H Sonobe; A Minami; H Hiraga; H Nishihara; H Sawa; K Nagashima
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.

Authors:  Alan L Ho; Shyamprasad Deraje Vasudeva; Marick Laé; Tsuyoshi Saito; Violetta Barbashina; Cristina R Antonescu; Marc Ladanyi; Gary K Schwartz
Journal:  Cancer Res       Date:  2012-07-10       Impact factor: 12.701

3.  Characterization of a novel radiation-induced sarcoma cell line.

Authors:  Julie Lang; Weizhu Zhu; Brandon Nokes; Grishma Sheth; Petr Novak; Laura Fuchs; George Watts; Bernard Futscher; Neal Mineyev; Alexander Ring; Lauren LeBeau; Ray Nagle; Lee Cranmer
Journal:  J Surg Oncol       Date:  2015-02-02       Impact factor: 3.454

4.  Interphase fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma.

Authors:  J Shipley; J Crew; S Birdsall; S Gill; J Clark; C Fisher; A Kelsey; T Nojima; H Sonobe; C Cooper; B Gusterson
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

5.  Effect of temozolomide on the viability of musculoskeletal sarcoma cells.

Authors:  Yuta Kusabe; Hiroyuki Kawashima; Akira Ogose; Taro Sasaki; Takashi Ariizumi; Tetsuo Hotta; Naoto Endo
Journal:  Oncol Lett       Date:  2015-07-17       Impact factor: 2.967

6.  The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.

Authors:  Ana Banito; Xiang Li; Aimée N Laporte; Jae-Seok Roe; Francisco Sanchez-Vega; Chun-Hao Huang; Amanda R Dancsok; Katerina Hatzi; Chi-Chao Chen; Darjus F Tschaharganeh; Rohit Chandwani; Nilgun Tasdemir; Kevin B Jones; Mario R Capecchi; Christopher R Vakoc; Nikolaus Schultz; Marc Ladanyi; Torsten O Nielsen; Scott W Lowe
Journal:  Cancer Cell       Date:  2018-03-01       Impact factor: 31.743

7.  Capacity for epithelial differentiation in synovial sarcoma: analysis of a new human cell line.

Authors:  T Yakushiji; K Yonemura; J Tsuruta; K Nishida; T Kato; K Takagi
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

Review 8.  Neuronal differentiation of synovial sarcoma and its therapeutic application.

Authors:  Tatsuya Ishibe; Tomitaka Nakayama; Tomoki Aoyama; Takashi Nakamura; Junya Toguchida
Journal:  Clin Orthop Relat Res       Date:  2008-06-19       Impact factor: 4.176

Review 9.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  Clin Dev Immunol       Date:  2010-10-11

10.  Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2'-deoxycytidine against synovial sarcoma cell lines.

Authors:  Kunihiko Numoto; Aki Yoshida; Shinsuke Sugihara; Toshiyuki Kunisada; Yuki Morimoto; Yasushi Yoneda; Yasuko Fujita; Keiichiro Nishida; Mamoru Ouchida; Toshifumi Ozaki
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.